BLENDER Trial

Blend to Limit oxygEN in ECMO:

A ranDomised controllEd Registry trial

A Phase II Multicentre Randomised Controlled Trial

Aim: Our aim is to determine in patients requiring venoarterial (V-A) ECMO, whether the use of a conservative as compared with liberal oxygen strategy, results in improved patient outcomes.

Rationale: There is a growing body of evidence that suggests high levels of oxygen may be harmful for our patients. In ECMO patients, the fraction of oxygen in the fresh gas delivered to the membrane (FbO2) was traditionally maintained at 1.0 (or 100% O2), however, in recent years a significant number of centres (within Australia and worldwide) are titrating the FbO2 according to patients’ needs. The variation in clinical practice is a result of the lack of evidence based guidelines. Current ECMO guidelines do not specify an optimal oxygen strategy and clinical equipoise exists.

In the BLENDER Trial we will determine if using a conservative versus a liberal approach to oxygen administration improves patient outcomes. If the BLENDER Trial confirms that one oxygen management strategy is more effective than the other, its findings may improve the lives of critically ill Australians and inform clinical practice worldwide.

Study Progress: Patient recruitment commenced in September 2019. A target of 300 patients will be enrolled from Victorian and interstate sites across Australia. Keep up to date with our progress and study updates on Twitter@BLENDER_RCT

Trial Registration: ClinicalTrials.gov ID: NCT03841084

Contact: For further information about this study, please contact the BLENDER Chief Investigator Professor David Pilcher, or the BLENDER Project Manager, Kelly Ottosen, by email.

Kelly Ottosen